Cuvitru 200 mg (Immunoglobulin (Human) SOLUTION) 200 MG

CUVITRU 200 MG is a subcutaneous solution containing immunoglobulin (human) for immune support. This medication is used to treat immune deficiencies and provide passive immunity.

Strength

200 MG

Manufacturer / TM Owner

TAKEDA CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

CUVITRU 200 MG is primarily used for immune support in individuals with primary immunodeficiency diseases. It helps to provide passive immunity by supplying antibodies that the body may not produce adequately. This medication is often prescribed to prevent infections in patients with weakened immune systems. What is CUVITRU used for? It is used to treat conditions where the immune system is not functioning properly, such as in primary immunodeficiency diseases.

Side Effects

Common effects of CUVITRU 200 MG may include reactions at the injection site, such as redness, swelling, or itching. Some individuals may experience headaches, fatigue, or muscle aches. These effects are generally mild and temporary. If you experience severe or persistent effects, consult a healthcare provider.

Precautions & Warnings

CUVITRU 200 MG should be handled with care. It is important to follow the prescribed administration guidelines and store the medication properly. Do not use if the solution appears cloudy or contains particles. Always inform your healthcare provider about any allergies or medical conditions before starting treatment.

Avoid Interactions

CUVITRU 200 MG may interact with certain medications, including those that affect the immune system. It is important to discuss all current medications with your healthcare provider to avoid potential interactions. Alcohol and other substances may also affect the body's response to this medication.

Frequently Asked Questions

CUVITRU 200 MG is used to treat primary immunodeficiency diseases and provide passive immunity.

CUVITRU 200 MG is administered subcutaneously, meaning it is injected under the skin.

Common effects may include reactions at the injection site, headaches, fatigue, or muscle aches.

It is important to discuss all current medications with your healthcare provider to avoid potential interactions.

Follow the storage instructions provided with the medication to ensure its effectiveness.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.